German drugmaker STADA Arzneimittel (SAZ: Xetra) is broadening its offering to patients, pharmacists and physicians in Europe by introducing abiraterone acetate 500mg film-coated tablets in 21 European countries. Used for treating metastatic prostate cancer, abiraterone adds to STADA's comprehensive oncology offering that spans oral and injectable medicines, including biological agents such as ... - The Pharma Letter